Concerto HealthAI is partnering with Pfizer to support the pharma company’s research into precision oncology treatments. Concerto will offer its AI-enabled abstraction and data science expertise to help Pfizer refine its study designs and to accelerate the completion times for outcomes studies. Pfizer will utilise Concerto's eurekaHealth platform, which uses data from the American Society of Clinical Oncology’s CancerLinQ to conduct outcomes study designs for different therapies and develop precision treatments. Concerto recently signed a Just weeks strategic agreement with Bristol-Myers Squibb.
Concerto HealthAI is partnering with Pfizer to support the pharma company’s research into precision oncology treatments. Concerto will offer its AI-enabled abstraction and data science expertise to help Pfizer refine its study designs and to accelerate the completion times for outcomes studies. Pfizer will utilise Concerto's eurekaHealth platform, which uses data from the American Society of Clinical Oncology’s CancerLinQ to conduct outcomes study designs for different therapies and develop precision treatments. Concerto recently signed a multi-year strategic agreement with Bristol-Myers Squibb.